Gevo (GEVO) Announces Proposed 43.75M Share Registered Direct Offering at $8/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
After-Hours Stock Movers 01/19: (NFLX) (CKPT) (PCAR) Higher; (HSTO) (BLRX) (ACRX) Lower (more...)
January 19, 2021 5:44 PM ESTAfter-Hours Stock Movers:
Histogen Inc. (NASDAQ: HSTO) 16.5% LOWER; announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the companys Investigational New Drug (IND) application package for the planned Phase 1/2 clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
BioLineRx Ltd. (NASDAQ:... More
Gevo (GEVO) files automatic mixed securities shelf coving an unspecified amount of securities
January 19, 2021 5:21 PM ESTGevo (NASDAQ: GEVO) files automatic mixed securities shelf coving an unspecified amount of securities.
... MorePre-Open Stock Movers 01/19: (ACRS) (GEVO) (GM) Higher; (PRPH) (EDIT) (MGI) Lower (more...)
January 19, 2021 9:27 AM ESTPre-Open Stock Movers:
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 128.4% HIGHER; announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris proprietary KINect drug discovery platform.
Gritstone Oncology, Inc. (NASDAQ: GRTS) 46.2% HIGHER; today announced that it... More
Gevo (GEVO) Co-founder Frances Arnold Named to President-Elect Joe Biden’s Science Team
January 19, 2021 9:18 AM ESTGevo, Inc. (NASDAQ: GEVO) announced today that Frances H. Arnold, a Nobel-Prize recipient and Gevos Co-Founder, has been named to President-Elect Joe Bidens Science Team. The Science Team is tasked with marshaling the force of science to drive meaningful progress in... More
UPDATE: Gevo, Inc. (GEVO) PT Raised to $8.25 at Noble Capital
January 19, 2021 7:31 AM EST(Updated - January 19, 2021 7:31 AM EST)
Noble Capital analyst Poe Fratt raised the price target on Gevo, Inc. (NASDAQ: GEVO) to $8.25 (from $5.00) while maintaining a Outperform rating.
The analyst comments "We believe the high risk/high reward profile remains attractive... More
